10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2012 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 15, 2013) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Cash flows from operating activities: | |||
| Net income (loss) | $ 750,269 | (221,760) | (104,468) |
| Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities: | |||
| Depreciation and amortization | 36,940 | 31,082 | 19,687 |
| Non-cash compensation expense | 94,157 | 56,094 | 39,897 |
| Non-cash interest expense | 22,925 | 5,101 | 43 |
| Other non-cash charges and expenses, net | 34,049 | 6,224 | 4,037 |
| Deferred taxes | (340,156) | ||
| Changes in assets and liabilites | |||
| Increase in Sanofi and trade accounts receivable | (590,085) | (21,118) | (17,518) |
| Increase in prepaid expenses and other assets | (52,616) | (6,992) | (8,212) |
| (Decrease) increase in deferred revenue | (41,077) | (40,329) | 158,151 |
| Increase in accounts payable, accrued expenses and other liabilities | 10,979 | 50,016 | 7,605 |
| Total adjustments | (824,884) | 80,078 | 203,690 |
| Net cash (used in) provided by operating activities | (74,615) | (141,682) | 99,222 |
| Cash flows from investing activities: | |||
| Purchases of marketable securities | (470,393) | (240,391) | (605,124) |
| Sales or maturities of marketable securities | 439,209 | 426,356 | 273,723 |
| Increase in restricted cash and marketable securities | (552) | (277) | (5,941) |
| Capital expenditures | (49,337) | (57,217) | (99,689) |
| Net cash(used in) provided by investing activities | (81,073) | 128,471 | (437,031) |
| Cash flows from financing activities: | |||
| Proceeds in connection with facility lease obligation | 47,544 | ||
| Payments in connection with facility and capital lease obligations | (2,203) | (1,667) | (1,028) |
| Proceeds in connection with issuance of convertible notes, net of debt issuance costs | 391,107 | ||
| Proceeds in connection with issuance of warrants | 93,800 | ||
| Payment in connection with purchase of convertible note hedges | (117,500) | ||
| Net proceeds from issuance of Common Stock | 63,549 | 43,587 | 200,588 |
| Payments in connection with Common Stock tendered for employee tax obligations | (163,300) | (25,078) | (3,798) |
| Excess tax benefit from stock-based compensation | 4,308 | ||
| Net cash (used in) provided by financing activities | (97,646) | 384,249 | 243,306 |
| Net (decrease) increase in cash and cash equivalents | (253,334) | 371,038 | (94,503) |
| Cash and cash equivalents at beginning of period | 483,610 | 112,572 | |
| Cash and cash equivalents at end of period | 230,276 | 483,610 | 112,572 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest | 21,946 | 14,725 | 12,737 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2012 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |